PL3558339T3 - Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania - Google Patents

Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania

Info

Publication number
PL3558339T3
PL3558339T3 PL17884258.9T PL17884258T PL3558339T3 PL 3558339 T3 PL3558339 T3 PL 3558339T3 PL 17884258 T PL17884258 T PL 17884258T PL 3558339 T3 PL3558339 T3 PL 3558339T3
Authority
PL
Poland
Prior art keywords
multimeralic
methods
cell modulating
modulating polypeptides
polypeptides
Prior art date
Application number
PL17884258.9T
Other languages
English (en)
Polish (pl)
Inventor
Iii Ronald D. Seidel
Rodolfo CHAPARRO
Original Assignee
Cue Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma, Inc. filed Critical Cue Biopharma, Inc.
Publication of PL3558339T3 publication Critical patent/PL3558339T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
PL17884258.9T 2016-12-22 2017-12-20 Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania PL3558339T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438272P 2016-12-22 2016-12-22
US201762470774P 2017-03-13 2017-03-13
US201762555435P 2017-09-07 2017-09-07
US201762582132P 2017-11-06 2017-11-06
PCT/US2017/067663 WO2018119114A1 (en) 2016-12-22 2017-12-20 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3558339T3 true PL3558339T3 (pl) 2024-08-05

Family

ID=62627190

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17884258.9T PL3558339T3 (pl) 2016-12-22 2017-12-20 Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania

Country Status (19)

Country Link
US (20) US20190352363A1 (enExample)
EP (2) EP3558339B1 (enExample)
JP (4) JP7250677B2 (enExample)
KR (1) KR102760578B1 (enExample)
CN (6) CN117024560A (enExample)
AU (1) AU2017379900B2 (enExample)
BR (1) BR112019012964A2 (enExample)
CA (1) CA3043630A1 (enExample)
DK (1) DK3558339T5 (enExample)
ES (1) ES2973548T3 (enExample)
IL (4) IL303806B2 (enExample)
MX (2) MX2019007611A (enExample)
MY (1) MY202029A (enExample)
PH (1) PH12019501413A1 (enExample)
PL (1) PL3558339T3 (enExample)
PT (1) PT3558339T (enExample)
SI (1) SI3558339T1 (enExample)
TW (2) TWI852752B (enExample)
WO (1) WO2018119114A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL303806B2 (en) 2016-12-22 2024-05-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20200064085A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132138A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020181062A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
MX2021014476A (es) * 2019-05-29 2022-02-11 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2020323893A1 (en) 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
AU2020348373A1 (en) * 2019-09-20 2022-02-24 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
EP4048689A4 (en) * 2019-10-23 2023-11-01 Cue Biopharma, Inc. T-CELL MODULATING CHIMERIC MOLECULES AND METHOD OF USE THEREOF
WO2021081232A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
EP4090674A4 (en) * 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021195108A1 (en) * 2020-03-24 2021-09-30 Cue Biopharma, Inc. T cell modulatory polypeptides and methods of use thereof
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202233673A (zh) 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
WO2023281481A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Antibody conjugates and manufacture thereof
AU2022306788A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
KR20240041379A (ko) 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Il-2에 접합된 체크포인트 억제제 및 이의 용도
US20250000946A1 (en) * 2021-09-26 2025-01-02 WuXi Biologics Ireland Limited Il-2 variants and fusion proteins thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
CN116036243A (zh) * 2022-04-20 2023-05-02 北京大学宁波海洋药物研究院 受体偏向的peg化il-2变体组合及其应用
TW202413442A (zh) 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2025059162A1 (en) * 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU675204B2 (en) 1992-06-25 1997-01-30 City Of Hope Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
GB9307371D0 (en) 1993-04-08 1993-06-02 Walls Alan J Fusion proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
DK0776339T4 (da) 1994-07-29 2010-05-25 Sunol Molecular Corp MHC-komplekser og anvendelser deraf
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US6218363B1 (en) 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998030693A2 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0979239B1 (en) 1997-02-13 2006-10-18 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
JP4480800B2 (ja) 1997-05-08 2010-06-16 オンコシリオン・インコーポレイテッド 活性化ｔ細胞および抗原パルス標識した抗原提示細胞を生成する方法
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US6960652B2 (en) * 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
CA2369747A1 (en) 1999-04-30 2000-11-09 The Trustees Of The University Of Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
CA2397741A1 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2001090747A2 (en) 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
WO2004029197A2 (en) 2001-06-22 2004-04-08 Maxygen, Inc. Co-stimulatory molecules
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US20030044847A1 (en) 2001-05-15 2003-03-06 Sidney Pestka Methods for anlyzing interactions between proteins in live and intact cells
EP1402006A4 (en) 2001-06-04 2005-11-23 Ml Lab Plc COMPOSITIONS AND METHODS FOR LARGE SCALE PRODUCTION AND HIGH EFFICIENCY OF RECOMBINANT PROTEINS
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002322211A1 (en) 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
AU2002363354A1 (en) 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
WO2003070763A1 (en) 2001-08-16 2003-08-28 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US6911321B2 (en) 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
CN101143221A (zh) 2002-03-15 2008-03-19 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
CA2516832A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
ES2559409T3 (es) 2003-09-05 2016-02-12 Oregon Health & Science University Moléculas de MHC recombinantes monoméricas útiles para la manipulación de células T específicas de antígenos
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
MX2007008017A (es) * 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CA2628959A1 (en) 2005-11-10 2007-06-07 Receptor Biologix, Inc. Methods for production of receptor and ligand isoforms
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
ZA200810677B (en) 2006-05-19 2010-03-31 Teva Pharma Fusion proteins, uses thereof and processes for producing same
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
NZ601175A (en) 2006-12-28 2012-12-21 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
EP2481418A1 (en) 2007-02-15 2012-08-01 MannKind Corporation A method for enhancing T cell response
WO2008113970A2 (en) 2007-03-16 2008-09-25 Ucl Business Plc Peptides
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (zh) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2445934B1 (en) 2009-06-25 2014-07-16 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2593551B1 (en) 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2673294B1 (en) * 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2667864T3 (es) 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
PT2726101T (pt) 2011-06-30 2018-11-21 Genzyme Corp Inibidores da ativação de células t
DE112011100879A5 (de) 2011-08-30 2013-11-14 Jacobs University Bremen Ggmbh Gen codiert für ein MHC-Klasse-I-Molekül, Plasmid, Expressionssystem, Protein, Multimer, Reagenz und Kit zum Analysieren einer T-Zellen-Frequenz
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
WO2014020069A1 (en) * 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
HK1211949A1 (en) 2012-11-30 2016-06-03 罗切格利卡特公司 Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
SG11201504414UA (en) * 2012-12-21 2015-07-30 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
KR20160007579A (ko) 2013-05-13 2016-01-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 면역요법의 임상 효과의 예측법
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
WO2015007903A1 (en) 2013-07-19 2015-01-22 Vib Vzw Targeted modified tnf family members
EP3027647A4 (en) * 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
WO2015112541A2 (en) 2014-01-21 2015-07-30 Albert Einstein College Of Medicine Of Yeshiva University Cellular platform for rapid and comprehensive t-cell immunomonitoring
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
CN106029699B (zh) 2014-02-26 2019-07-19 泰来有限公司 Wt1抗原性多肽和含有该多肽的抗肿瘤剂
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
EP3480213B1 (en) 2014-06-18 2019-11-13 Albert Einstein College of Medicine Syntac polypeptides and uses thereof
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
IL289475B2 (en) 2014-07-21 2023-10-01 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA2957717C (en) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
MY193723A (en) 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
EP3223850B1 (en) 2014-11-26 2020-01-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-mutated kras t cell receptors
SG10201908203SA (en) 2015-03-05 2019-10-30 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins And Uses Thereof
CN115873129A (zh) 2015-03-23 2023-03-31 约翰·霍普金斯大学 由体细胞突变基因编码的hla限制性表位
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
KR102859521B1 (ko) 2015-05-06 2025-09-12 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
CA2986367A1 (en) 2015-05-20 2016-11-24 Sumitomo Dainippon Pharma Co., Ltd. Combination use of wt1 antigen peptide and immunomodulator
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
EP3322715B1 (en) 2015-07-14 2023-10-18 BioNTech SE Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
CA2993429A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CN106565836B (zh) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
KR20250099263A (ko) 2015-11-20 2025-07-01 메모리얼 슬로안 케터링 캔서 센터 암 치료 방법 및 조성물
CA3009799A1 (en) 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particles encapsulating fusion proteins containing linked epitopes
CN115969987A (zh) 2016-01-11 2023-04-18 鲁比厄斯治疗法股份有限公司 与免疫适应症的多模式治疗性细胞体系有关的组合物和方法
SG10201911561SA (en) 2016-01-27 2020-02-27 CSL Behring Lengnau AG Recombinant igg fc multimers
US20190062400A1 (en) 2016-03-02 2019-02-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7372036B2 (ja) 2016-03-03 2023-10-31 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3022331A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
CN110177558B (zh) 2016-09-16 2025-02-28 贝勒医学院 用于病毒特异性t细胞的活化和扩增的平台
AU2017357865B2 (en) 2016-11-09 2024-10-31 Uti Limited Partnership Recombinant pMHC class II molecules
IL303806B2 (en) 2016-12-22 2024-05-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
EP3446702A1 (en) 2017-08-23 2019-02-27 Medizinische Hochschule Hannover Synthetic vaccine
KR20200064083A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 항원-제시 폴리펩티드 및 이의 사용 방법
KR20200064085A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
TW201925235A (zh) 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
EA202090471A1 (ru) 2017-09-07 2020-06-10 Кью Биофарма, Инк. Модулирующие т-клетки мультимерные полипептиды и способы их применения
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2019162937A1 (en) 2018-02-20 2019-08-29 Technion Research & Development Foundation Limited Immunotherapeutic composition for the treatment of cancer
MX2021003938A (es) 2018-10-05 2021-08-11 Int Inst Cancer Immunology Inc Composicion para prevenir o tratar un tumor benigno.
WO2020132366A2 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132365A2 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132368A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132138A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132135A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132136A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP7691927B2 (ja) 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
WO2020181062A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20220282217A1 (en) 2019-03-30 2022-09-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
MX2021014476A (es) 2019-05-29 2022-02-11 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CA3142738A1 (en) 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
WO2020257191A1 (en) 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2020348373A1 (en) 2019-09-20 2022-02-24 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
EP4048689A4 (en) 2019-10-23 2023-11-01 Cue Biopharma, Inc. T-CELL MODULATING CHIMERIC MOLECULES AND METHOD OF USE THEREOF
WO2021081232A1 (en) 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
US20230143831A1 (en) 2020-02-28 2023-05-11 National University Corporation Kanazawa University Antigen-presenting extracellular vesicles, composition containing same, and method for production thereof
US20230117521A1 (en) 2020-03-25 2023-04-20 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
GB202005617D0 (en) 2020-04-17 2020-06-03 Adaptimmune Ltd Improved t cell manufacturing process
CA3182959A1 (en) 2020-05-12 2021-11-18 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
CN113823723A (zh) * 2020-06-18 2021-12-21 光宝光电(常州)有限公司 发光二极管封装结构
US20230279076A1 (en) 2020-07-14 2023-09-07 Cue Biopharma, Inc. T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
TW202233673A (zh) 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
US20240082411A1 (en) 2020-11-06 2024-03-14 Cue Biopharma, Inc. T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
WO2022119958A1 (en) 2020-12-02 2022-06-09 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20230129983A (ko) 2020-12-09 2023-09-11 애셔 바이오테라퓨틱스, 인크. 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
WO2022125694A1 (en) 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
EP4308143A4 (en) 2021-03-19 2025-06-04 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
US20240197846A1 (en) 2021-04-22 2024-06-20 Cue Biopharma, Inc. Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
WO2023081718A1 (en) 2021-11-04 2023-05-11 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CA3236566A1 (en) 2021-11-24 2023-06-01 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2023137156A2 (en) 2022-01-13 2023-07-20 Cue Biopharma, Inc. T cell modulatory polypeptides with conjugation sites and methods of use thereof

Also Published As

Publication number Publication date
IL297617B1 (en) 2023-07-01
PT3558339T (pt) 2024-03-15
US11739133B2 (en) 2023-08-29
US11530248B2 (en) 2022-12-20
US20230399372A1 (en) 2023-12-14
JP7295325B2 (ja) 2023-06-20
US20240199715A1 (en) 2024-06-20
EP4360647A2 (en) 2024-05-01
SI3558339T1 (sl) 2024-05-31
US20200199181A1 (en) 2020-06-25
US20200207824A1 (en) 2020-07-02
CA3043630A1 (en) 2018-06-28
IL308851B1 (en) 2025-03-01
BR112019012964A2 (pt) 2019-10-08
TW201829451A (zh) 2018-08-16
US20190352363A1 (en) 2019-11-21
ES2973548T3 (es) 2024-06-20
US12152061B2 (en) 2024-11-26
US11117945B2 (en) 2021-09-14
US20250243253A1 (en) 2025-07-31
JP7250677B2 (ja) 2023-04-03
IL266696B (en) 2022-12-01
CN116970061A (zh) 2023-10-31
US20250092110A1 (en) 2025-03-20
US20210107962A1 (en) 2021-04-15
TWI869327B (zh) 2025-01-11
CN117903282A (zh) 2024-04-19
US11851467B2 (en) 2023-12-26
IL266696A (en) 2019-07-31
EP3558339A4 (en) 2020-08-19
IL303806B2 (en) 2024-05-01
EP3558339B1 (en) 2024-01-24
IL266696B2 (en) 2023-04-01
US11905320B2 (en) 2024-02-20
US11370821B2 (en) 2022-06-28
KR102760578B1 (ko) 2025-02-03
PH12019501413A1 (en) 2020-03-16
IL308851B2 (en) 2025-07-01
IL297617B2 (en) 2023-11-01
JP2023113888A (ja) 2023-08-16
IL308851A (en) 2024-01-01
EP4360647A3 (en) 2024-07-24
JP7560641B2 (ja) 2024-10-02
US20220064247A1 (en) 2022-03-03
WO2018119114A1 (en) 2018-06-28
JP7403703B2 (ja) 2023-12-22
US11708400B2 (en) 2023-07-25
CN116970059A (zh) 2023-10-31
US11401314B2 (en) 2022-08-02
US11505588B2 (en) 2022-11-22
US10927158B2 (en) 2021-02-23
TWI852752B (zh) 2024-08-11
US11377478B2 (en) 2022-07-05
KR20190111022A (ko) 2019-10-01
EP3558339A1 (en) 2019-10-30
US20220356224A1 (en) 2022-11-10
CN110325205A (zh) 2019-10-11
JP2020511949A (ja) 2020-04-23
US20240141006A1 (en) 2024-05-02
CN117024560A (zh) 2023-11-10
IL303806B1 (en) 2024-01-01
US12145973B2 (en) 2024-11-19
AU2017379900B2 (en) 2024-12-05
MY202029A (en) 2024-03-29
US20230257439A1 (en) 2023-08-17
CN110325205B (zh) 2023-08-15
US20210198337A1 (en) 2021-07-01
JP2023027295A (ja) 2023-03-01
MX2023013883A (es) 2023-12-11
US20230220032A1 (en) 2023-07-13
DK3558339T5 (da) 2024-09-02
IL303806A (en) 2023-08-01
US12180258B2 (en) 2024-12-31
US20240083964A1 (en) 2024-03-14
US12421287B2 (en) 2025-09-23
US20220033456A1 (en) 2022-02-03
US20220289808A1 (en) 2022-09-15
CN116970060A (zh) 2023-10-31
US20220340632A1 (en) 2022-10-27
JP2024037852A (ja) 2024-03-19
IL297617A (en) 2022-12-01
MX2019007611A (es) 2020-07-29
US11987610B2 (en) 2024-05-21
US20240076344A1 (en) 2024-03-07
TW202400216A (zh) 2024-01-01
AU2017379900A1 (en) 2019-06-13
US20220177536A1 (en) 2022-06-09
DK3558339T3 (da) 2024-02-26

Similar Documents

Publication Publication Date Title
PL3558339T3 (pl) Multimeryczne polipeptydy modulujące limfocyty t i sposoby ich stosowania
IL271025A (en) Multibiotic agents and methods of using the same
IL272085A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
IL282372A (en) Haploid induction compositions and methods for use therefor
DK3534899T3 (da) Forbindelser og fremgangsmåder til modulering af interleukin-2-inducerbar t-cellekinase
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3551660T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3249777T3 (da) Adapter og fremgangsmåde til opladningskontrol
DK3464282T3 (da) Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3221357T3 (da) Fælles letkæder og fremgangsmåder til anvendelse
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
PL3551664T3 (pl) Przeciwciała i polipeptydy skierowane przeciwko cd127
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania